Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can radiofrequency heat thaw a frozen shoulder?

NCT ID NCT07785583

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study tests whether adding TECAR therapy—a device that delivers radiofrequency energy to warm deep tissues—to standard physical therapy can improve pain, pressure sensitivity, and range of motion in postmenopausal women with frozen shoulder. Forty women aged 50-60 with stage II frozen shoulder will receive either conventional physical therapy alone or combined with TECAR. Researchers will measure pain, disability, and shoulder movement before and after treatment to see if the added therapy offers extra benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Capacitive Resistive Energy Transfer (TECAR) therapy, a device-based treatment that uses radiofrequency energy to heat deep tissues, combined with conventional physical therapy (stretching, strengthening, and manual therapy).
What this could lead to
If effective, TECAR therapy could offer a non-invasive, drug-free option to reduce pain and improve shoulder mobility in postmenopausal women with frozen shoulder.
What could go wrong
This is a small, early-stage trial with only 40 participants, so results may not apply broadly. The therapy may not outperform standard physical therapy alone, and there is a risk of discomfort or skin irritation from the device.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sedentary, ambulatory, non-smoking women. * Postmenopausal women with at least one-year amenorrhea. * Having natural menopause at least one year prior to participating in the study. * No history of bilateral surgical removal of the ovaries and/or the uterus. * Women with age of 50-60 years. * Their body mass index (BMI) will be ≤ 30 kg/m2. * The parity number will be 2-4 times. * Diagnosed with unilateral frozen shoulder (adhesive capsulitis) - Stage II (frozen stage). * Patients with moderate to severe shoulder pain (Pain score ≥ 4 on the visual analogue scale). Exclusion Criteria: * Diabetes. * Osteoporosis. * Previous shoulder surgeries. * History of tumor. * Bilateral frozen shoulder. * Upper extremity fractures or cervical radiculopathy. * Impaired sensation or heart pacemaker. * Any autoimmune disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Frozen shoulder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bursitis frozen shoulder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Frozen shoulder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cairo university

    Giza, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.